Foundation models and AI agents in oncology drug discovery
{{output}}
Oncology drug discovery remains limited by high attrition, slow experimental iteration and weak translation from preclinical models to clinical benefit. This review examines how AI is restructuring that process through three connected layers: biological founda... ...
